Wordt geladen...
Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
PURPOSE: Azacitidine (AZA) is the current standard of care for high-risk (ie, International Prognostic Scoring System high or intermediate 2) myelodysplastic syndrome (MDS), but most patients will experience primary or secondary treatment failure. The outcome of these patients has not yet been descr...
Bewaard in:
| Gepubliceerd in: | J Clin Oncol |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Society of Clinical Oncology
2011
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4859209/ https://ncbi.nlm.nih.gov/pubmed/21788559 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.35.8135 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|